The estimated Net Worth of R Bradley Gray is at least $21.1 millió dollars as of 6 May 2024. Mr. Gray owns over 617,230 units of Nanostring Technologies Inc stock worth over $116,723 and over the last 11 years he sold NSTG stock worth over $13,741,225. In addition, he makes $7,288,840 as President, Chief Executive Officer és Director at Nanostring Technologies Inc.
R has made over 35 trades of the Nanostring Technologies Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 617,230 units of NSTG stock worth $64,994 on 6 May 2024.
The largest trade he's ever made was exercising 617,230 units of Nanostring Technologies Inc stock on 6 May 2024 worth over $64,994. On average, R trades about 26,356 units every 40 days since 2014. As of 6 May 2024 he still owns at least 1,108,477 units of Nanostring Technologies Inc stock.
You can see the complete history of Mr. Gray stock trades at the bottom of the page.
R. Bradley Gray serves as President, Chief Executive Officer, Director of the Company. Mr. Gray held various positions at Genzyme, a biotechnology company acquired by Sanofi in 2011. He served as Vice President of Product & Business Development for Genzyme Genetics, the diagnostic services division of Genzyme, from June 2008 to May 2010, leading the development of molecular diagnostics and partnering activities. From September 2006 to June 2008, he served as Vice President of Business & Strategic Development for Genzyme Genetics, leading growth efforts through partnerships and licensing. Mr. Gray joined Genzyme in October 2004 as Director of Corporate Development, supporting business development and leading Genzyme Ventures, the corporate venture capital fund of Genzyme. Prior to joining Genzyme, Mr. Gray was a management consultant in the healthcare practice of McKinsey & Company, a global management consulting firm, from September 2000 to October 2004, where he worked with senior healthcare executives in the United States and Europe on a broad range of issues including pharmaceutical and diagnostic product strategy, post-merger integration, organization design, and operational turnarounds. Mr. Gray received a B.A. in Economics and Management from Oxford University, where he studied as a British Marshall Scholar, and an S.B. in Chemical Engineering from the Massachusetts Institute of Technology.
As the President, Chief Executive Officer és Director of Nanostring Technologies Inc, the total compensation of R Gray at Nanostring Technologies Inc is $7,288,840. There are no executives at Nanostring Technologies Inc getting paid more.
R Gray is 43, he's been the President, Chief Executive Officer és Director of Nanostring Technologies Inc since 2010. There are 18 older and no younger executives at Nanostring Technologies Inc. The oldest executive at Nanostring Technologies Inc is William Young, 75, who is the Independent Chairman of the Board.
R's mailing address filed with the SEC is 530 FAIRVIEW AVENUE N, , SEATTLE, WA, 98109.
Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus... és Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.
nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali
Nanostring Technologies Inc executives and other stock owners filed with the SEC include: